Jefferies Financial Group Inc. Sells 3,872 Shares of Charles River Laboratories International, Inc. $CRL

Jefferies Financial Group Inc. reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 43.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,000 shares of the medical research company’s stock after selling 3,872 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Charles River Laboratories International were worth $782,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in CRL. Norges Bank purchased a new position in shares of Charles River Laboratories International in the second quarter valued at about $76,952,000. National Bank of Canada FI grew its stake in shares of Charles River Laboratories International by 1,179.5% in the second quarter. National Bank of Canada FI now owns 434,868 shares of the medical research company’s stock worth $65,983,000 after purchasing an additional 400,881 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in shares of Charles River Laboratories International by 722.5% in the second quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock worth $65,885,000 after purchasing an additional 381,432 shares during the last quarter. Ariel Investments LLC increased its holdings in Charles River Laboratories International by 28.6% during the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after purchasing an additional 314,572 shares during the period. Finally, LSV Asset Management increased its holdings in Charles River Laboratories International by 1,773.0% during the 3rd quarter. LSV Asset Management now owns 297,800 shares of the medical research company’s stock valued at $46,594,000 after purchasing an additional 281,900 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 9.9%

Charles River Laboratories International stock opened at $152.22 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The company has a market capitalization of $7.49 billion, a price-to-earnings ratio of -51.43, a price-to-earnings-growth ratio of 2.89 and a beta of 1.64. The business’s fifty day simple moving average is $192.53 and its two-hundred day simple moving average is $180.94. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s revenue was down .8% on a year-over-year basis. During the same period last year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. TD Cowen dropped their price objective on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a report on Friday, February 20th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a research note on Monday, December 1st. Barclays decreased their target price on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, February 19th. Evercore raised their price target on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, UBS Group boosted their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Ten analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $203.57.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.